electroCore (ECOR) Registration Filing summary

Company overview and business model

• Commercial-stage bioelectronic technology company focused on non-invasive neuromodulation for health and wellness applications.

• Key products include gammaCore (FDA-cleared for primary headache), Quell Fibromyalgia, Truvaga (consumer wellness), and TAC-STIM (human performance).

• Revenue streams from U.S. and select international markets, with major customers including the U.S. Department of Veterans Affairs, Department of Defense, and UK NHS.

• Recent acquisition of NeuroMetrix, Inc. to expand offerings in chronic pain management.

Financial performance and metrics

• Sales to the VA comprised 70.3% of revenue for the three months ended March 31, 2025; UK NHS sales under the Med Tech Funding Mandate comprised 5.3%.

• The company qualifies as a “smaller reporting company” under SEC rules, allowing for scaled disclosure and reduced compliance requirements.

• The independent auditor’s report includes a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for sales and marketing, working capital, and general corporate purposes.

• May allocate funds to acquisitions, in-licenses, or investments in complementary businesses or technologies as opportunities arise.

• Management retains broad discretion over the application of proceeds.